Lilly Pulls FDA Application For Cymbalta For Pain

Nov 28, 2008

CHICAGO (Reuters) – Eli Lilly and Co (LLY.N: Quote, Profile, Research, Stock Buzz) said on Friday it withdrew an application to market its anti-depressant Cymbalta for the management of chronic pain because U.S. health regulators raised questions about the drug’s effectiveness and dosing.

Lilly said it made its decision to pull the supplemental New Drug Application for Cymbalta, or duloxetine HCl, after U.S. Food and Drug Administration reviewers questioned the design of supporting Lilly studies and statistical methodology. More…

PainCareMD